A case of glioblastoma resected immediately after administering bevacizumab: consideration on histopathological findings and safety of surgery

Yukina Tokuda, Ryota Tamura, Kentaro Ohara, Kazunari Yoshida, Hikaru Sasaki

研究成果: Article

抄録

Surgery after administering bevacizumab should be carefully considered particularly because of wound healing concerns. A 27-year-old man presented with multiple tumor recurrences after gross total removal of a left temporal oligodendroglioma (1p/19q-noncodeleted). Whole brain radiotherapy with concomitant temozolomide and bevacizumab was immediately prescribed; however, the patient’s condition deteriorated because of brain herniation. Three days after administering bevacizumab, an emergency tumor removal with external decompression and a ventriculo-peritoneal shunt was performed. The surgery and postoperative clinical course were uneventful. On histopathological examination, the tumor showed findings such as tumor vessel thrombosis, numerous interstitial red blood cells, and cells with degraded, fragmented nuclei possibly suggesting apoptosis, which could be attributable to bevacizumab. Performing craniotomy shortly after administering bevacizumab is not recommended; however, it can still be safely performed as long as surgery and wound management is carefully performed. Vessel thrombosis might be among the mechanisms of action of bevacizumab.

元の言語English
ページ(範囲)98-102
ページ数5
ジャーナルBrain Tumor Pathology
34
発行部数2
DOI
出版物ステータスPublished - 2017 4 1

Fingerprint

Glioblastoma
Safety
temozolomide
Neoplasms
Thrombosis
Oligodendroglioma
Ventriculoperitoneal Shunt
Craniotomy
Brain
Decompression
Wound Healing
Bevacizumab
Emergencies
Radiotherapy
Erythrocytes
Apoptosis
Recurrence
Wounds and Injuries

ASJC Scopus subject areas

  • Oncology
  • Clinical Neurology
  • Cancer Research

これを引用

@article{4b39c55de5a848b2bb741cadf269a494,
title = "A case of glioblastoma resected immediately after administering bevacizumab: consideration on histopathological findings and safety of surgery",
abstract = "Surgery after administering bevacizumab should be carefully considered particularly because of wound healing concerns. A 27-year-old man presented with multiple tumor recurrences after gross total removal of a left temporal oligodendroglioma (1p/19q-noncodeleted). Whole brain radiotherapy with concomitant temozolomide and bevacizumab was immediately prescribed; however, the patient’s condition deteriorated because of brain herniation. Three days after administering bevacizumab, an emergency tumor removal with external decompression and a ventriculo-peritoneal shunt was performed. The surgery and postoperative clinical course were uneventful. On histopathological examination, the tumor showed findings such as tumor vessel thrombosis, numerous interstitial red blood cells, and cells with degraded, fragmented nuclei possibly suggesting apoptosis, which could be attributable to bevacizumab. Performing craniotomy shortly after administering bevacizumab is not recommended; however, it can still be safely performed as long as surgery and wound management is carefully performed. Vessel thrombosis might be among the mechanisms of action of bevacizumab.",
keywords = "Bevacizumab, Craniotomy, Glioblastoma, Thrombosed microvessels",
author = "Yukina Tokuda and Ryota Tamura and Kentaro Ohara and Kazunari Yoshida and Hikaru Sasaki",
year = "2017",
month = "4",
day = "1",
doi = "10.1007/s10014-017-0285-9",
language = "English",
volume = "34",
pages = "98--102",
journal = "Brain Tumor Pathology",
issn = "1433-7398",
publisher = "Springer Japan",
number = "2",

}

TY - JOUR

T1 - A case of glioblastoma resected immediately after administering bevacizumab

T2 - consideration on histopathological findings and safety of surgery

AU - Tokuda, Yukina

AU - Tamura, Ryota

AU - Ohara, Kentaro

AU - Yoshida, Kazunari

AU - Sasaki, Hikaru

PY - 2017/4/1

Y1 - 2017/4/1

N2 - Surgery after administering bevacizumab should be carefully considered particularly because of wound healing concerns. A 27-year-old man presented with multiple tumor recurrences after gross total removal of a left temporal oligodendroglioma (1p/19q-noncodeleted). Whole brain radiotherapy with concomitant temozolomide and bevacizumab was immediately prescribed; however, the patient’s condition deteriorated because of brain herniation. Three days after administering bevacizumab, an emergency tumor removal with external decompression and a ventriculo-peritoneal shunt was performed. The surgery and postoperative clinical course were uneventful. On histopathological examination, the tumor showed findings such as tumor vessel thrombosis, numerous interstitial red blood cells, and cells with degraded, fragmented nuclei possibly suggesting apoptosis, which could be attributable to bevacizumab. Performing craniotomy shortly after administering bevacizumab is not recommended; however, it can still be safely performed as long as surgery and wound management is carefully performed. Vessel thrombosis might be among the mechanisms of action of bevacizumab.

AB - Surgery after administering bevacizumab should be carefully considered particularly because of wound healing concerns. A 27-year-old man presented with multiple tumor recurrences after gross total removal of a left temporal oligodendroglioma (1p/19q-noncodeleted). Whole brain radiotherapy with concomitant temozolomide and bevacizumab was immediately prescribed; however, the patient’s condition deteriorated because of brain herniation. Three days after administering bevacizumab, an emergency tumor removal with external decompression and a ventriculo-peritoneal shunt was performed. The surgery and postoperative clinical course were uneventful. On histopathological examination, the tumor showed findings such as tumor vessel thrombosis, numerous interstitial red blood cells, and cells with degraded, fragmented nuclei possibly suggesting apoptosis, which could be attributable to bevacizumab. Performing craniotomy shortly after administering bevacizumab is not recommended; however, it can still be safely performed as long as surgery and wound management is carefully performed. Vessel thrombosis might be among the mechanisms of action of bevacizumab.

KW - Bevacizumab

KW - Craniotomy

KW - Glioblastoma

KW - Thrombosed microvessels

UR - http://www.scopus.com/inward/record.url?scp=85018468796&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018468796&partnerID=8YFLogxK

U2 - 10.1007/s10014-017-0285-9

DO - 10.1007/s10014-017-0285-9

M3 - Article

C2 - 28429093

AN - SCOPUS:85018468796

VL - 34

SP - 98

EP - 102

JO - Brain Tumor Pathology

JF - Brain Tumor Pathology

SN - 1433-7398

IS - 2

ER -